Proportional upregulation of CD97 isoforms in glioblastoma and glioblastoma-derived brain tumor initiating cells

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Safaee, Michael ^a   Fakurnejad, Shayan ^b   Bloch, Orin ^b   Clark, Aaron J ^a   Ivan, Michael E ^a   Sun, Matthew Z ^a   Oh, Taemin ^b   Phillips, Joanna J ^a   Parsa, Andrew T ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD97 ANTIGEN; CHONDROITIN SULFATE; ISOCITRATE DEHYDROGENASE 1; VERY LATE ACTIVATION ANTIGEN 5; CD97 PROTEIN, HUMAN; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; LEUKOCYTE ANTIGEN; RNA ISOFORM;

ARTICLE; ASTROCYTOMA; CANCER STEM CELL; CONTROLLED STUDY; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGAND BINDING; LOW GRADE ASTROCYTOMA; OVERALL SURVIVAL; TUMOR INVASION; UPREGULATION; ALTERNATIVE RNA SPLICING; BRAIN TUMOR; CANCER GRADING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY;

ALTERNATIVE SPLICING; ANTIGENS, CD; BRAIN NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; NEOPLASM GRADING; NEOPLASTIC STEM CELLS; RNA ISOFORMS;

EID: 84923899594     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111532     Document Type: Article

References (62)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. PMID: 15758009
2. Laws ER, Parney IF, Huang W, Anderson F, Morris AM, et al. (2003) Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 99: 467-473. PMID: 12959431
3. Parsa AT, Wachhorst S, Lamborn KR, Prados MD, McDermott MW, et al. (2005) Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults. J Neurosurg 102: 622-628. PMID: 15871503
4. Safaee M, Clark AJ, Oh MC, Ivan ME, Bloch O, et al. (2013) Overexpression of CD97 Confers an Invasive Phenotype in Glioblastoma Cells and Is Associated with Decreased Survival of Glioblastoma Patients. PLoS One 8: e62765. doi: 10.1371/journal.pone.0062765 PMID: 23658650
5. Yona S, Lin HH, Siu WO, Gordon S, Stacey M (2008) Adhesion-GPCRs: emerging roles for novel receptors. Trends Biochem Sci 33: 491-500. doi: 10.1016/j.tibs.2008.07.005 PMID: 18789697
6. Eichler W, Hamann J, Aust G (1997) Expression characteristics of the human CD97 antigen. Tissue Antigens 50: 429-438. PMID: 9389316
7. Hamann J, Vogel B, van Schijndel GM, van Lier RA (1996) The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J Exp Med 184: 1185-1189. PMID: 9064337
8. Stacey M, Chang GW, Davies JQ, Kwakkenbos MJ, Sanderson RD, et al. (2003) The epidermal growth factor-like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans. Blood 102: 2916-2924. PMID: 12829604
9. Hamann J, Stortelers C, Kiss-Toth E, Vogel B, Eichler W, et al. (1998) Characterization of the CD55 (DAF)-binding site on the seven-span transmembrane receptor CD97. Eur J Immunol 28: 1701-1707. PMID: 9603477
10. Qian YM, Haino M, Kelly K, Song WC (1999) Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55). Immunology 98: 303-311. PMID: 10540231
11. Wang T, Ward Y, Tian L, Lake R, Guedez L, et al. (2005) CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. Blood 105: 2836-2844. PMID: 15576472
12. Tchaicha JH, Reyes SB, Shin J, Hossain MG, Lang FF, et al. (2011) Glioblastoma angiogenesis and tumor cell invasiveness are differentially regulated by beta8 integrin. Cancer Res 71: 6371-6381. doi: 10.1158/0008-5472.CAN-11-0991 PMID: 21859829
13. Friedlander DR, Zagzag D, Shiff B, Cohen H, Allen JC, et al. (1996) Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves alphaV and beta1 integrins. Cancer Res 56: 1939-1947. PMID: 8620517
14. Schrappe M, Klier FG, Spiro RC, Waltz TA, Reisfeld RA, et al. (1991) Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Res 51: 4986-4993. PMID: 1893386
15. Steinert M, Wobus M, Boltze C, Schutz A, Wahlbuhl M, et al. (2002) Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. Am J Pathol 161: 1657-1667. PMID: 12414513
16. Holting T, Siperstein AE, Clark OH, Duh QY (1995) Epidermal growth factor (EGF)- and transforming growth factor alpha-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro. Eur J Endocrinol 132: 229-235. PMID: 7858744
17. Aust G, Steinert M, Schutz A, Boltze C, Wahlbuhl M, et al. (2002) CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic, and esophageal carcinomas. Am J Clin Pathol 118: 699-707. PMID: 12428789
18. Aust G, Eichler W, Laue S, Lehmann I, Heldin NE, et al. (1997) CD97: a dedifferentiation marker in human thyroid carcinomas. Cancer Res 57: 1798-1806. PMID: 9135025
19. Galle J, Sittig D, Hanisch I, Wobus M, Wandel E, et al. (2006) Individual cell-based models of tumorenvironment interactions: Multiple effects of CD97 on tumor invasion. Am J Pathol 169: 1802-1811. PMID: 17071601
20. Chidambaram A, Fillmore HL, Van Meter TE, Dumur CI, Broaddus WC (2012) Novel report of expression and function of CD97 in malignant gliomas: correlation with Wilms tumor 1 expression and glioma cell invasiveness. J Neurosurg 116: 843-853. doi: 10.3171/2011.11.JNS111455 PMID: 22313360
21. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, et al. (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5: 67. PMID: 17140455
22. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760. PMID: 17051156
23. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, et al. (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66: 7843-7848. PMID: 16912155
24. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, et al. (2007) CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67: 4010-4015. PMID: 17483311
25. Tamase A, Muraguchi T, Naka K, Tanaka S, Kinoshita M, et al. (2009) Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin. Proc Natl Acad Sci U S A 106: 17163-17168. doi: 10.1073/pnas.0905016106 PMID: 19805150
26. Chen J, Li Y, Yu TS, McKay RM, Burns DK, et al. (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488: 522-526. doi: 10.1038/nature11287 PMID: 22854781
27. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, et al. (2009) Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4: 568-580. doi: 10.1016/j.stem.2009.03.014 PMID: 19497285
28. Sun Y, Pollard S, Conti L, Toselli M, Biella G, et al. (2008) Long-term tripotent differentiation capacity of human neural stem (NS) cells in adherent culture. Mol Cell Neurosci 38: 245-258. doi: 10.1016/j.mcn. 2008.02.014 PMID: 18450476
29. Brosseau JP, Lucier JF, Lapointe E, Durand M, Gendron D, et al. (2010) High-throughput quantification of splicing isoforms. RNA 16: 442-449. doi: 10.1261/rna.1877010 PMID: 20038630
30. Liu D, Trojanowicz B, Ye L, Li C, Zhang L, et al. (2012) The invasion and metastasis promotion role of CD97 small isoform in gastric carcinoma. PLoS One 7: e39989. doi: 10.1371/journal.pone.0039989 PMID: 22768192
31. Lin HH, Stacey M, Saxby C, Knott V, Chaudhry Y, et al. (2001) Molecular analysis of the epidermal growth factor-like short consensus repeat domain-mediated protein-protein interactions: dissection of the CD97-CD55 complex. J Biol Chem 276: 24160-24169. PMID: 11297558
32. Durrant LG, Chapman MA, Buckley DJ, Spendlove I, Robins RA, et al. (2003) Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol Immunother 52: 638-642. PMID: 12811528
33. Liu Y, Chen L, Peng SY, Chen ZX, Hoang-Vu C (2005) Role of CD97(stalk) and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients. J Zhejiang Univ Sci B 6: 913-918. PMID: 16130195
34. Liu Y, Chen L, Peng S, Chen Z, Gimm O, et al. (2005) The expression of CD97EGF and its ligand CD55 on marginal epithelium is related to higher stage and depth of tumor invasion of gastric carcinomas. Oncol Rep 14: 1413-1420. PMID: 16273233
35. Wu J, Lei L, Wang S, Gu D, Zhang J (2012) Immunohistochemical expression and prognostic value of CD97 and its ligand CD55 in primary gallbladder carcinoma. J Biomed Biotechnol 2012: 587672. doi: 10.1155/2012/587672 PMID: 22547928
36. Tonn JC, Wunderlich S, Kerkau S, Klein CE, Roosen K (1998) Invasive behaviour of human gliomas is mediated by interindividually different integrin patterns. Anticancer Res 18: 2599-2605. PMID: 9703915
37. Rooprai HK, Vanmeter T, Panou C, Schnull S, Trillo-Pazos G, et al. (1999) The role of integrin receptors in aspects of glioma invasion in vitro. Int J Dev Neurosci 17: 613-623. PMID: 10571422
38. Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, et al. (2012) Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol 106: 147-153. doi: 10.1007/s11060-011-0650-1 PMID: 21739168
39. Scaringi C, Minniti G, Caporello P, Enrici RM (2012) Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. Anticancer Res 32: 4213-4223. PMID: 23060541
40. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004) Identification of human brain tumour initiating cells. Nature 432: 396-401. PMID: 15549107
41. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, et al. (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64: 7011-7021. PMID: 15466194
42. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, et al. (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9: 391-403. PMID: 16697959
43. Yu SP, Yang XJ, Zhang B, Ming HL, Chen C, et al. (2011) Enhanced invasion in vitro and the distribution patterns in vivo of CD133+ glioma stem cells. Chin Med J (Engl) 124: 2599-2604. PMID: 22040410
44. Cheng L, Wu Q, Guryanova OA, Huang Z, Huang Q, et al. (2011) Elevated invasive potential of glioblastoma stem cells. Biochem Biophys Res Commun 406: 643-648. doi: 10.1016/j.bbrc.2011.02. 123 PMID: 21371437
45. Qiu B, Zhang D, Tao J, Tie X, Wu A, et al. (2012) Human brain glioma stem cells are more invasive than their differentiated progeny cells in vitro. J Clin Neurosci 19: 130-134. doi: 10.1016/j.jocn.2011.06.014 PMID: 22153826
46. Biddle A, Liang X, Gammon L, Fazil B, Harper LJ, et al. (2011) Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res 71: 5317-5326. doi: 10.1158/0008-5472.CAN-11-1059 PMID: 21685475
47. Cancer Genome Atlas Research N (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068. doi: 10.1038/nature07385 PMID: 18772890
48. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110. doi: 10.1016/j.ccr.2009.12.020 PMID: 20129251
49. Tso CL, Freije WA, Day A, Chen Z, Merriman B, et al. (2006) Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res 66: 159-167. PMID: 16397228
50. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, et al. (2007) Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 104: 20007-20012. PMID: 18077431
51. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, et al. (2006) Molecular subclasses of highgrade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173. PMID: 16530701
52. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, et al. (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116: 597-602. doi: 10.1007/s00401-008-0455-2 PMID: 18985363
53. Bleeker FE, Atai NA, Lamba S, Jonker A, Rijkeboer D, et al. (2010) The prognostic IDH1 (R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol 119: 487-494. doi: 10.1007/s00401-010-0645-6 PMID: 20127344
54. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, et al. (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118: 469-474. doi: 10.1007/s00401-009-0561-9 PMID: 19554337
55. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, et al. (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27: 4150-4154. doi: 10.1200/ JCO.2009.21.9832 PMID: 19636000
56. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174: 1149-1153. doi: 10.2353/ajpath. 2009.080958 PMID: 19246647
57. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773. doi: 10.1056/NEJMoa0808710 PMID: 19228619
58. Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, et al. (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11: 341-347. doi: 10.1215/15228517-2009-025 PMID: 19435942
59. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15: 6002-6007. doi: 10.1158/1078-0432.CCR-09-0715 PMID: 19755387
60. Ward Y, Lake R, Yin JJ, Heger CD, Raffeld M, et al. (2011) LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells. Cancer Res 71: 7301-7311. doi: 10.1158/0008-5472.CAN-11-2381 PMID: 21978933
61. Ward Y, Lake R, Martin PL, Killian K, Salerno P, et al. (2012) CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model. Oncogene.
62. Lin ME, Herr DR, Chun J (2010) Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat 91: 130-138. doi: 10.1016/j.prostaglandins.2009. 02.002 PMID: 20331961